H.C. Wainwright raised the firm's price target on Oruka Therapeutics to $120 from $75 and keeps a Buy rating on the shares. The EVERLAST-A "delivers in spades," positioning ORKA-001 as a best-in-disease agent with an optimized convenience profile, the analyst tells investors in a research note. The firm views the EVERLAST-A data as a "best-case scenario,: positioning ORKA-001 as a possible leading psoriasis medication that may be "preferred by the lion's share of patients due to the potential for once-yearly dosing." It increased the probability of approval for ORKA-001 to 75% from 50% in psoriasis.
